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ABSTRACT
To determine the graft-versus-leukemia effect after hematopoietic stem cell transplantation (HSCT), we
studied 199 patients with acute lymphoblastic leukemia who underwent transplantation at Huddinge
University Hospital between 1981 and 2001. Seventy-four patients were in first complete remission (CR1),
and 125 were in later stages of the disease. Most patients had an HLA-identical sibling donor. Condi-
tioning consisted mainly of total body irradiation and cyclophosphamide, and graft-versus-host disease
(GVHD) prophylaxis consisted of cyclosporine and methotrexate. Acute GVHD developed in 143 patients
and chronic GVHD in 67. The 5-year probability of relapse and relapse-free survival (RFS) were 32% and
49%, respectively, in patients in CR1, as compared with 53% and 33% in those with more advanced
disease. In the multivariate risk factor analysis of relapse, we found that the absence of chronic GVHD (P <
.001), absence of herpes simplex virus infection after HSCT (P  .003), combination prophylaxis with
methotrexate and cyclosporine (P  .01), and >6 weeks from the diagnosis to CR (P  .025) were
independent risk factors for relapse after HSCT. Factors associated with a better relapse-free survival
were chronic GVHD (P < .001), ABO blood group mismatch (P  .006), younger patient age (P  .01), and
an HLA-matched donor (P  .01). The association between herpes simplex virus infection and a low
frequency of relapse is a new observation and may indicate that viral antigens play a role in the induction
of an antileukemic effect.
© 2004 American Society for Blood and Marrow Transplantation
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ANTRODUCTION
Patients with acute lymphoblastic leukemia (ALL)
un a higher risk of relapse after hematopoietic stem
ell transplantation (HSCT) than those with other
ematologic malignancies [1,2]. Graft-versus-host dis-
ase (GVHD) is a major complication after HSCT,
ut it is also closely correlated with the development
f the beneﬁcial graft-versus-leukemia (GVL) effect
3-5]. Patients with mild acute or chronic GVHD run
signiﬁcantly lower risk of leukemia relapse after
SCT than those without GVHD [3-5]. Chronic H
B&MTVHD is associated with an antileukemia effect and
ontributes to an improved survival after allogeneic
SCT [3-5]. It is still unclear whether the antitumor
ffect is mediated by the same or different immune
ells as GVHD [1,3,6,7]. The correlation between
VHD and GVL is mainly seen in non–T cell–de-
leted grafts. In T cell–depleted grafts, the intensity
nd frequency of GVHD and GVL are markedly
educed [5,8,9]. In this study, we evaluated risk factors
or relapse and the GVL effect in 199 patients with
LL who were given HSCT at Huddinge University
ospital between 1981 and 2001.
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1ATIENTS AND MATERIALS
atients
One hundred ninety-nine patients with ALL un-
erwent HSCT at Huddinge University Hospital be-
ween 1981 and 2001 (Table 1). One hundred four-
een (57%) were children younger than 18 years of
ge, and 85 were adults. Among patients with a mis-
atched related donor (n  12), 9 had an HLA-DR–
ismatched, 2 an HLA-B–mismatched, and 1 a hap-
otype-mismatched donor. Among patients with an
able 1. Patient and Donor Characteristics
Factor Data
199
edian recipient age (y), range 15 (1-60)
ecipient sex (male/female) 123/76
edian donor age (y), range 25 (2-62)
onor sex (male/female) 103/96
onor
HLA-identical sibling 118 (59%)
HLA-identical related 3 (1.5%)
Mismatched related 12 (6%)
HLA-matched unrelated 50 (25%)
Mismatched unrelated (allele level) 9 (5%)
Mismatched unrelated 7 (3.5%)
ubtypes
ALL unspecified 22
B-cell ALL 131
T-cell ALL 46
Philadelphia chromosome/4;11 translocation 30/6
isease stage
CR1 74 (38%)
CR2 82 (40%)
CR3-5 22 (11%)
Partial remission 10 (5%)
Relapse 11 (5.5%)
ucleated cell dose (108/kg), median (range) 2.9 (0.2-26.9)
onimmunized female donor to male
recipient 37 (19%)
mmunized female donor to male recipient 19 (9.5%)
BO blood group compatibility
Identical 115 (58%)
Minor mismatch 59 (30%)
Major mismatch 25 (13%)
ays from diagnosis to HSCT 378 (53-5224)
tem cell source (bone marrow/peripheral
blood) 176/23
onditioning
TBI 10 Gy  cyclophosphamide (Cy) 135 (67%)
TBI 7.5 Gy  Cy 8 (4%)
Fractionated TBI (4  3 Gy)  Cy 38 (19%)
Busulfan  Cy 18 (9%)
VHD prophylaxis
Methotrexate (MTX) 35 (18%)
Cyclosporine (CsA) 19 (9.5%)
MTX  CsA 126 (63%)
T-cell depletion 14 (7%)
Prednisolone  CsA 4 (2%)
CsA  mycophenolate mofetil 1 (0.5%)
-CSF after HSCT 74 (37%)
-CSF indicates granulocyte colony-stimulating factor.llele level–mismatched unrelated donor (n  9), 5 t
96ere mismatched at the HLA-B locus and 4 at HLA-
R. Whole-antigen mismatched unrelated donors
n  7) consisted of 3 HLA-A, 2 HLA-B, and 2
LA-DR mismatches.
Before the transplantation, 53 (42%) of 125 pa-
ients beyond ﬁrst complete remission (CR1) had a
elapse while still receiving therapy, 33 had high leu-
ocyte counts (100  109/L) at diagnosis, and 72
ere considered to be slow responders, deﬁned as 6
eeks from the diagnosis to their ﬁrst CR. Among the
hildren, 25% were in CR1, as compared with 55% of
he adults. Children who underwent transplantation in
R1 had high-risk criteria, such as the Philadelphia
hromosome (n  7), the 4:11 translocation (n  1),
r a high leukocyte count at diagnosis (n  4) or were
low responders (n  2).
onditioning
Most of the patients received cyclophosphamide
Cy) 60 mg/kg on 2 consecutive days combined with
0 Gy of total body irradiation (TBI), with the lungs
hielded to receive no more than 9 Gy (Table 1) [10].
hirty-eight patients were treated with fractionated
BI 3 Gy for 4 days combined with Cy 120 mg/kg.
ight patients given a T cell–depleted graft were
onditioned with Cy 120 mg/kg and 3  2 Gy of total
ymph node irradiation, followed by 7.5 Gy of TBI
11]. Eighteen patients received busulfan (4 mg/kg/
 4) and Cy (60 mg/kg  2) [12].
Matched unrelated donor (MUD) recipients re-
eived 3 to 5 days of treatment (days 5 to 1) with
ither antithymocyte globulin (IMTIX-Sangstat,
yon, France, or Fresenius AG, Gra¨felﬁng, Germany)
n a dose of 2 to 5 mg/kg/d or OKT-3 (Janssen-Cilag,
ug, Switzerland) 5 mg/d before transplantation [13].
ll patients were given 2 doses of intrathecal metho-
rexate (MTX) 12 mg or cytarabine 30 mg before
SCT.
VHD Prophylaxis
Most patients received cyclosporine (CsA) com-
ined with a short course of MTX [14,15]. Intrave-
ous CsA in a dose ranging from 5 to 10 mg/kg/d was
tarted on day 1 in patients with MUD and from 1
o 3 mg/kg/d in patients with HLA-identical sibling
onors. During the ﬁrst month, blood CsA levels were
ept at 200 to 300 ng/mL in those with MUD and at
pproximately 100 ng/mL in those with sibling donors
16]. After 6 months, in MUD transplant recipients,
he CsA dose was decreased by 25% every alternate
onth and discontinued after 12 months in the ab-
ence of GVHD. In sibling transplant recipients, CsA
as discontinued after 3 to 6 months. Fourteen pa-
ients with an HLA-mismatched graft received a T
ell–depleted graft and no immunosuppression after
ransplantation [11]. Other protocols included CsA
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GVL Effect after HSCT in ALL
Bombined with steroids or mycophenolate mofetil
17]. Some patients received MTX or CsA alone, as
escribed in detail elsewhere [18].
efinitions
Bone marrow (BM) aspirates were taken at 3, 6,
nd 12 months and then yearly after HSCT. Regen-
rating peripheral blood values were considered as
linical remission when 5% blasts per 200 nucleated
ells were found.
Leukemic relapse was deﬁned as 30% blasts in
M or extramedullary leukemic cells—ie, extramed-
llary relapse. The presence of 5% to 30% blasts in
he marrow was regarded as an early relapse. Molec-
lar relapse was considered as increasing levels of
CR/ABL transcript in the peripheral blood, BM
amples in Philadelphia chromosome–positive ALL,
r increasing levels of recipient cells in the leukemia-
ffected cell lineage [19]. A herpes simplex virus
HSV) infection was deﬁned as a positive HSV isola-
ion or positive immunoﬂuorescence from lesions or a
ositive polymerase chain reaction (PCR).
iagnosis and Treatment of GVHD
Acute GVHD was diagnosed on the basis of clin-
cal symptoms or biopsy samples of skin, oral mucosa,
iver, and gut. GVHD was graded from 0 to IV [20].
t the ﬁrst sign of grade I GVHD, prednisolone 2
g/kg/d was given [21]. Severe or persistent GVHD
as treated with antithymocyte globulin [22] or pso-
alen and ultraviolet light [23,24]. Chronic GVHD
as diagnosed on the basis of clinical symptoms or
iopsy samples from the skin, oral mucosa, liver, and
ut.
tem Cell Source and Supportive Care
One hundred seventy-six patients received BM,
nd 23 received stem cells from peripheral blood.
ranulocyte colony-stimulating factor was given to 74
37%) of the patients from day 10 after HSCT until
he absolute neutrophil count reached 0.5  109/L
or 2 consecutive days [25]. Since 1986, prophylaxis
ith acyclovir (ACV), 200 mg  4 by mouth daily
ntil day 30 after HSCT, has been given to all patients
ith an HSV serotiter of 10000. Before 1986, a few
atients included in a randomized study received ACV
s prophylaxis. Some patients were also included in a
ytomegalovirus prophylactic study that compared
CV and valacyclovir in various doses.
LA Typing
Before 1997, HLA class I typing was serologic.
ince then, we have used PCR sequence-speciﬁc
rimer low-resolution typing for class I. Since July
992, the PCR methods with sequence-speciﬁc
rimer pairs have been used [26]. All patients with w
B&MTnrelated donors have recently been retrospectively
etyped by using PCR sequence-speciﬁc primer high-
esolution typing for both HLA class I and II antigens
27].
tatistics
The time to relapse was determined with the life
able method by using the log-rank (Mantel-Haens-
el) test, taking censored data into account. The Cox
egression model was used for the univariate and mul-
ivariate analyses [28]. The time to relapse was used to
alculate the cumulative incidence curves, and death
as a censored observation, unless relapse had oc-
urred. When relapse was analyzed, patients who died
ithin 90 days of HSCT without a relapse were ex-
luded. Thirty-two risk factors for relapse were stud-
ed (Table 2). Only factors at 10% levels in the
nivariate analyses were introduced into the stepwise
limination multivariate analysis. We performed only
multivariate analysis for each event. Therefore, no
onferroni correction was performed. A female donor
as considered to be immunized if she had been preg-
ant or had had a blood transfusion. Patients in CR1
ere considered to have early disease, and all other
tages were considered to be late diseases.
ESULTS
raft-versus-Host Disease
Six patients died within 30 days of HSCT without
cute GVHD and were not included in the analysis of
cute GVHD. Fifty patients (26%) had no sign of
cute GVHD. Of the remaining patients, 98 (51%)
eveloped grade I, 30 (16%) grade II, and 15 (8%)
rade III or IV. The cumulative incidences of acute
VHD grades II to IV were 17%, 28%, and 40% in
rafts from HLA-identical siblings, MUD, or HLA-
ismatched donors, respectively. The corresponding
gures for chronic GVHD were 48%, 52%, and 41%.
elapse
Twenty patients died within 90 days of HSCT.
ecurrent disease was diagnosed in 70 (68 morpho-
ogically and 2 molecularly) of the 179 remaining
atients. Fifty-one (73%) of the relapses occurred
ithin 1 year of HSCT. The cumulative probability of
elapse was 32% at 5 years in patients with early
isease and 53% in those with advanced disease (P 
01). The probabilities of relapse in patients with an
LA-identical sibling donor, mismatched related do-
or, MUD, and mismatched unrelated donor were
8%, 53%, 48%, and 68%, respectively.
isk Factors for Relapse
In the Cox regression univariate analysis, 6 factors
ere signiﬁcant at the 5% level. We also included 3
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1dditional factors signiﬁcant at the 10% level in the
ultivariate analysis (Table 2). In the stepwise elimi-
ation multivariate analysis, stratiﬁed for disease stage
nd corrected for transplantation year and occurrence
f the t(9;22) or t(4;11) translocations, the absence of
hronic GVHD (P  .001), absence of HSV infection
P  .003), GVHD prophylaxis with CsA and MTX
P  .01), and being a slow responder (P  .025) were
ndependent risk factors for relapse in this study (Ta-
le 3). If chronic GVHD was not included in the
nalysis, absence of HSV infection (hazard ratio [HR],
.30; 95% conﬁdence interval [CI], 1.98-20.0; P 
002) and being a slow responder (HR, 1.84; 95% CI,
.06-3.19; P  .03) were independent risk factors for
elapse. The probability of relapse in patients with or
ithout chronic GVHD, in patients with and without
n HSV infection, those with monotherapy versus
ombination prophylaxis, and slow responders versus
apid responders is shown in Figure 1. The relapse
ates did not differ between B-lineage (43%) and T-
able 2. Cox Regression: Univariate Analysis of Risk Factors for Relap
ymphoblastic Leukemia
Factor N
ecipient sex Male/femal
ecipient age In decades
onor Others/sibl
Related/unr
LA match Match/mism
isease status CR1/>CR1
Remission/n
SCT year 5-y increme
ucleated cell dose (108/kg) <2.9/>2.9
BO Match/mism
onor sex Male/femal
onor age In decades
onditioning TBI/busulfa
Others/fTB
VHD prophylaxis Monothera
rophylaxis Others/TcD
ime from diagnosis to HSCT <1/>1 y
emale donor to male recipient No/yes
mmunized female donor to male No/yes
tem cell source BM/PBSC
-CSF after HSCT No/yes
cute GVHD No/yes
0-I/II-IV
hronic GVHD No/yes
SV infection No/yes
MV infection No/yes
h or t(4;11) No/yes
elapse on therapy No/yes
eukocyte count at diagnosis <100/>100
ime from diagnosis to CR <6/>6 wk
ecipient CMV serostatus /
onor CMV serostatus /
R indicates complete remission; HSCT, hematopoietic stem cell
fractionated TBI; GVHD, graft-versus-host disease; G-CSF, g
cytomegalovirus; TcD, T-cell depletion; Ph, Philadelphia chrineage (49%) ALL. The probability of relapse among C
98atients with Philadelphia chromosome–positive or
(4;11) ALL in CR1 (n  24) was 46%, as compared
ith 25% in patients (in CR1) without these translo-
ations (n  46; P  .08).
elapse or Death (RFS) in 199 HSCT Patients with Acute
Relapse
P Value
RFS
P Value
.64 .78
.71 .01
.16 .24
.31 .84
.13 .002
.01 .01
ission .22 .40
.06 .63
.70 .28
.20 .02
.36 .27
.51 .09
.72 .98
.07 .25
bination .10 .55
.65 .99
.07 .16
.53 .32
.56 .05
.82 .92
.24 .89
.009 .04
.05 .29
<.001 <.001
.002 .04
.84 .63
.92 .79
.22 .007
/L .45 .53
.028 .11
.77 .26
.52 .22
lantation; ABO, blood groups; TBI, total body irradiation; fTBI,
yte colony-stimulating factor; HSV, herpes simplex virus; CMV,
e positive; PBSC, peripheral blood stem cells.
able 3. Results of the Multivariate Analysis of Factors Associated
ith Relapse and Treatment Failure Stratiﬁed for Disease Stage
nd Corrected for Transplantation Year and Occurrence of
he t(9;22) and t(4;11) Translocations
Factor HR 95% CI P Value
elapse
No chronic GVHD 3.82 1.82-8.00 <.001
No HSV infection 6.17 1.82-20.9 .003
Combination GVHD
prophylaxis 2.56 1.22-5.37 .01
Slow responder 1.95 1.07-3.56 .025
FS
No chronic GVHD 2.59 1.65-4.06 <.001
ABO match 1.82 1.19-2.86 .006
HLA mismatch 2.08 1.20-3.60 .01
Higher recipient age 1.19 1.03-1.36 .01se and R
o/Yes
e
ing
elated
atch
o rem
nts
atch
e
n
I
py/com
 109
transp
ranuloc
omosomI indicates conﬁdence interval; HR  hazard ratio.
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Belapse-Free Survival
Relapse-free survival (RFS) in all patients was
9%. Among patients with a sibling donor or a MUD,
FS was 41% and 43% at 5 years, respectively. In
atients with a mismatched related or unrelated do-
or, the corresponding ﬁgures were 25% and 19%,
espectively.
In the univariate analysis of RFS, we found 9
actors to be signiﬁcant at the 5% level and 1 factor at
he 10% level (Table 2). In the multivariate analysis,
hronic GVHD (P  .001), an ABO blood group
ntigen–mismatched graft (P  .006), younger patient
ge (P  .01), and an HLA-matched donor (P  .01)
orrelated with a better RFS (Table 3). When chronic
VHD was excluded, factors correlated with better
FS were an HLA-matched donor (HR, 1.97; P 
004), lower patient age (HR, 1.25; P  .003), CR1
HR, 1.79; P  .006), and an ABO-mismatched graft
HR, 1.49; P  .04; Figure 2). Improved RFS was
ainly seen in minor ABO mismatches (antirecipient
emagglutinins in the donor). Patients with an ABO-
ismatched donor had a trend for lower relapse rates
38% versus 50%; P  .2) and a lower nonrelapse
ortality (21% versus 34%; P  .04) than those with
igure 1. Probability of relapse in patients with or without 4 risk
implex virus infection, (c) GVHD prophylaxis, and (d) time to init
atients were initially included in the non-GVHD arm. Once they
gure).n ABO-matched donor. v
B&MTSV Infection
A total of 40 (20%) patients had a documented
SV infection after HSCT. None of the patients had
life-threatening HSV infection. Three of these pa-
ients died before day 90. Fifty-six patients were sero-
egative and 140 were seropositive for HSV at trans-
lantation. Among the seropositive patients, 53 had
igh titers (10000), and 81 had low titers. In 6
atients, the HSV titer was not available. An HSV
nfection occurred more frequently among the sero-
ositive patients than seronegative ones (26% versus
%; P  .002). The seropositive patients with high
iters had signiﬁcantly more HSV infections than the
ow-titer patients (43% versus 16%; P  .001). Since
986, when we started to give ACV prophylaxis, the
ncidence of HSV infections has declined among pa-
ients with high pretransplantation HSV titers, and
nfections occur later. In this patient population, no
orrelation was found between HSV serostatus and
elapse. The median number of days to HSV infection
id not differ between patients with or without a
elapse (26 versus 41 days, respectively). An HSV
nfection was more common in adults than in children
28% versus 14%; P  .02). The effects of an HSV
nfection and chronic GVHD on various outcome
for relapse after HSCT for ALL: (a) chronic GVHD, (b) herpes
onse on therapy after diagnosis (univariate comparisons). In (a), all
ed GVHD, they were moved into the GVHD arm (left truncatedfactors
ial resp
developariables are shown in Table 4.
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2onor Lymphocyte Infusion Treatment
Eleven of the patients who relapsed were treated
ith a donor lymphocyte infusion (DLI). Nine of
hese patients had a morphologic relapse, and 2 had a
olecular relapse. Four (36%) patients responded, but
relapsed again after a short remission (2 months);
he others remain in remission 16 to 28 months after
he DLI. Of the 4 who responded, 3 had a morpho-
ogic relapse and 1 a molecular relapse. Among the 11
LI-treated patients, 8 had no acute GVHD, 1 de-
eloped grade I, 1 developed grade II, and 1 developed
rade IV acute GVHD. Chronic GVHD developed in
patients. Another 9 patients who relapsed received a
econd transplant from the same donor. Eight of them
ied a median of 64 days (range, 5 days to 2.7 years)
igure 2. Probability of relapse-free survival in patients with or wit
VHD, (b) ABO blood group compatibility, (c) HLA match, and
atients were initially included in the non-GVHD arm. Once they
gure).
able 4. The Effects of HSV Infection and Chronic GVHD on
utcome after HSCT in Patients with ALL: Actuarial 5-Year
robabilities
HSV
Infection
Chronic
GVHD n TRM Survival Relapse RFS
No No 91 19% 30% 62% 30%
Yes No 19 31% 49% 26% 50%
No Yes 48 16% 60% 32% 57%
Yes Yes 18 26% 74% 7% 68%
RM indicates transplant-related mortality; RFS, relapse-free sur-
avival.
00fter the second transplantation. The surviving patient
s in complete remission after 3 years. The median
ime from the ﬁrst transplantation to relapse was 1.9
ears (range, 0.3-3.6 years), and the median time from
elapse to a second transplantation was 68 days (range,
3-155 days). Four of the patients who underwent
etransplantation died when they relapsed after the
econd transplantation. Other causes of death in this
roup were 1 each of fungal infection, interstitial
neumonia, acute GVHD, and lung edema.
ISCUSSION
The role of GVL in ALL is uncertain. Some
tudies report little, if any, effect of an acute GVHD
lone, whereas others have found a lower incidence of
elapse after acute or chronic GVHD, or both, than
ith no GVHD and have found that chronic GVHD
as a stronger antileukemia effect than acute GVHD
2-5,29-33].
Because chemotherapy is curative in most children
ith ALL, only the most severe cases undergo trans-
lantation, and these account for a high relapse rate. It
as recently been shown that many of the patients
ith ALL considered to be in complete remission had
igh levels of minimal residual disease, which is also
risk factors for treatment failure after HSCT for ALL: (a) chronic
sease stage at transplantation (univariate comparisons). In (a), all
ed GVHD, they were moved into the GVHD arm (left truncatedhout 4
(d) di
developssociated with an increase in the relapse rate [34,35].
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GVL Effect after HSCT in ALL
Bhis may indicate that ALL is less responsive to a
VL effect than other hematologic malignancies or
hat the GVL effect may not have the time to arrest a
apidly developing disease in acute leukemia patients
ith minimal residual disease before the transplanta-
ion.
We found that GVHD and the type of GVHD
rophylaxis affected the incidence of relapse. This has
een reported previously [3-5,36,37]. However, with
etter immune prophylaxis, the GVHD-associated
ortality is reduced and results in unaffected RFS.
An association between herpes virus serology and
VHD was reported [38,39]. The correlation be-
ween an HSV infection and a lower risk of relapse
ould be indirect and due to GVHD. However, we
ound a similar incidence of both acute and chronic
VHD in patients with or without an HSV infection.
oreover, in the multivariate analysis, the correlation
etween an HSV infection and a lower incidence of
elapse was independent of GVHD. Another explana-
ion may be that HSV infections have an antileukemia
ffect. Using an animal model, Toda et al. [40] showed
hat the inoculation of tumor cells with HSV virus
nhibited tumor growth by local cytotoxic viral repli-
ation initiating a systemic antitumor immune re-
ponse. Other studies have found that replication-
ompetent HSV-1 is cytolytic to tumor cells and thus
nhibits tumor growth in vivo in both immune-deﬁ-
ient and immune-competent animals [41-44]. This
ould be due to the lytic destruction of tumor cells
eleasing tumor antigens that are picked up by anti-
en-presenting cells and carried to the draining lymph
odes, where they are processed and presented to
D8 T cells. Associative recognition of HSV-spe-
iﬁc and tumor-speciﬁc antigens may also play a role
n the strength of the response. HSV-infected tumor
ells would have maturing virions budding from their
ell membranes and may also process viral antigens for
HC class I presentation, like antigen-presenting
ells. The HSV-infected tumor cells could, therefore,
irectly induce T cell–mediated immune reactions.
ome of the immune response induced by co-presen-
ation of viral and tumor antigens may be triggered
hereafter by only 1 of the coexpressed antigens. Our
ata suggest that HSV replication after HSCT may
nduce leukemia cell lysis, a systemic immune re-
ponse against malignant cells, or both, possibly
hrough T or natural killer cells. However, this hy-
othesis must be proven in appropriate experiments.
atient age, pretransplantation HSV serology, and a
ore toxic conditioning regimen may serve as surro-
ate factors for an HSV infection, but the inclusion of
hese surrogate factors in the multivariate analysis did
ot change the results.
In this study, we also evaluated well-known
igh-risk criteria, such as “slow responder,” high
eukocyte count at diagnosis, relapse while still on S
B&MTherapy, and 9;22 or 4;11 translocation. Patients
ho were considered to be slow responders ran a
igniﬁcantly higher risk of relapse after transplan-
ation than those who responded more quickly
53% versus 35%; P  .03; Figure 1). This associ-
tion was still apparent in the multivariate analysis
P  .03). These patients may have a more resistant
isease in which the conditioning therapy and the
VL effect are less potent.
We found an association between ABO blood
roup mismatch and better RFS. This is controversial
ut is in line with Metha et al. [45], who reported an
ssociation between ABO mismatch and a lower re-
apse rate and better overall and disease-free survival
n BM transplantation patients with acute myeloid
eukemia.
An association between higher patient age and
orse RFS was found. This is well known; older pa-
ients are more susceptible to toxic effects from the
onditioning and do not tolerate GVHD and its treat-
ent as well as younger patients.
We found an association between an HLA-mis-
atched graft and a worse RFS, but there was no
ssociation with relapse. One would think that pa-
ients with mismatched or unrelated donors would run
higher risk of GVHD and, therefore, have a lower
isk of relapse. However, many patients with a mis-
atched donor received a T cell–depleted graft. T-
ell depletion entails a lower risk of GVHD but a
igher risk of relapse and infections, a slower immune
econstitution, and lower survival [46,47].
The response rates to DLI depend on the time of
elapse, disease, induction of GVHD, and grade of
isease at treatment [48]. The best results have been
ound in patients with chronic myeloid leukemia,
hereas ALL patients have very low response rates
49,50], suggesting a limited GVL effect in this group
f patients. However, in our study, DLI treatment
nduced remission in 4 (36%) of 11 treated patients, as
as also shown by Slavin et al. [51]. Therefore, DLI
reatment in patients with relapsed ALL after HSCT
ay be effective in some patients.
We conclude that chronic GVHD and HSV in-
ection were associated with a lower relapse rate,
hereas more effective GVHD prophylaxis and being
slow responder were associated with a higher rate.
he association between an HSV infection and fewer
elapses is a new observation and may indicate a role
f viral antigens in the induction of an antileukemic
ffect. However, the retrospective nature of this anal-
sis, coupled with the 20-year span, increases the need
or caution in interpreting these ﬁndings.
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